MA27509A1 - Formulations a liberation prolongee contenant de la lamotrigine - Google Patents
Formulations a liberation prolongee contenant de la lamotrigineInfo
- Publication number
- MA27509A1 MA27509A1 MA28074A MA28074A MA27509A1 MA 27509 A1 MA27509 A1 MA 27509A1 MA 28074 A MA28074 A MA 28074A MA 28074 A MA28074 A MA 28074A MA 27509 A1 MA27509 A1 MA 27509A1
- Authority
- MA
- Morocco
- Prior art keywords
- sustained release
- lamotrigin
- release formulations
- formulations containing
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Abstract
L'invention concerne une formulation à libération prolongée contenant de la lamotrigine, ou un dérivé de la lamotrigine acceptable sur le plan pharmaceutique, ainsi que des méthodes de traitement et des procédés d'utilisation de ces formulations.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0217492A GB0217492D0 (en) | 2002-07-29 | 2002-07-29 | Novel method of treatment |
GB0217493A GB0217493D0 (en) | 2002-07-29 | 2002-07-29 | Novel methods of treatment |
GB0313801A GB0313801D0 (en) | 2003-06-13 | 2003-06-13 | Novel methods of treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27509A1 true MA27509A1 (fr) | 2005-09-01 |
Family
ID=31499035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28074A MA27509A1 (fr) | 2002-07-29 | 2005-01-28 | Formulations a liberation prolongee contenant de la lamotrigine |
Country Status (29)
Country | Link |
---|---|
US (1) | US20050032799A1 (fr) |
EP (1) | EP1524981B1 (fr) |
JP (2) | JP4744142B2 (fr) |
KR (1) | KR100882707B1 (fr) |
CN (1) | CN100363007C (fr) |
AR (1) | AR040709A1 (fr) |
AT (1) | ATE424827T1 (fr) |
AU (1) | AU2003260336C1 (fr) |
BR (1) | BRPI0313148B8 (fr) |
CA (1) | CA2493301A1 (fr) |
CO (1) | CO5680405A2 (fr) |
CY (1) | CY1109119T1 (fr) |
DE (1) | DE60326590D1 (fr) |
DK (1) | DK1524981T3 (fr) |
ES (1) | ES2323268T3 (fr) |
HK (1) | HK1077003A1 (fr) |
IL (1) | IL166424A (fr) |
IS (1) | IS2681B (fr) |
MA (1) | MA27509A1 (fr) |
MX (1) | MXPA05001243A (fr) |
MY (1) | MY141049A (fr) |
NO (1) | NO334221B1 (fr) |
NZ (1) | NZ537885A (fr) |
PL (1) | PL213565B1 (fr) |
PT (1) | PT1524981E (fr) |
RU (1) | RU2325163C2 (fr) |
SI (1) | SI1524981T1 (fr) |
TW (1) | TWI342213B (fr) |
WO (1) | WO2004012741A1 (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7939102B2 (en) * | 2002-06-07 | 2011-05-10 | Torrent Pharmaceuticals Ltd. | Controlled release formulation of lamotrigine |
PL213565B1 (pl) * | 2002-07-29 | 2013-03-29 | Glaxo Group Ltd | Preparat o przedluzonym uwalnianiu zawierajacy lamotrygine |
JP2007512350A (ja) * | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール組成物の治療および送達方法 |
WO2006023347A1 (fr) * | 2004-08-20 | 2006-03-02 | Alpharma, Inc. | Formulations à base de paroxétine |
JP5666087B2 (ja) * | 2005-04-06 | 2015-02-12 | アダマス・ファーマシューティカルズ・インコーポレーテッド | Cns関連疾患の治療のための方法及び組成物 |
WO2008109343A1 (fr) * | 2007-03-01 | 2008-09-12 | Memory Pharmaceuticals Corporation | Procédés de traitement des troubles bipolaires et des déficiences de la mémoire et/ou cognitives associées avec ceux-ci avec du (+)-4-(2-chloro-3-cyanophényl)-1,4-dihydro-2,6-diméthylpyridine-3,5-dicarboxylate d'isopropyle et de 2-méthoxyéthyle |
US20090022789A1 (en) * | 2007-07-18 | 2009-01-22 | Supernus Pharmaceuticals, Inc. | Enhanced formulations of lamotrigine |
WO2009061513A1 (fr) * | 2007-11-09 | 2009-05-14 | Thar Pharmaceuticals | Formes cristallines de lamotrigine |
US20090196924A1 (en) * | 2008-02-04 | 2009-08-06 | Pramod Kharwade | Controlled-release lamotrigine formulations |
US20100323016A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
US20100323015A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
US20100120906A1 (en) * | 2008-07-18 | 2010-05-13 | Valeant Pharmaceuticals International | Modified release formulation and methods of use |
CA2782556C (fr) | 2009-12-02 | 2018-03-27 | Adamas Pharmaceuticals, Inc. | Compositions d'amantadine et procedes d'utilisation associes |
WO2011086568A1 (fr) * | 2010-01-13 | 2011-07-21 | Accutest Research Laboratories (I) Pvt. Ltd | Composition à libération contrôlée pour la lamotrigine |
MX2013008946A (es) * | 2011-02-03 | 2013-10-25 | Lupin Ltd | Composiciones farmaceuticas orales de bepotastina de liberacion controlada. |
WO2014159275A1 (fr) * | 2013-03-14 | 2014-10-02 | PharmTak, Inc. | Compositions pharmaceutiques à libération contrôlée comprenant de la lamotrigine et procédés de production de celles-ci |
CN103920134A (zh) * | 2014-05-08 | 2014-07-16 | 崔韡 | 一种治疗儿童眩晕的缓释片及其制备方法 |
RU2624229C2 (ru) * | 2015-12-21 | 2017-07-03 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Таблетки клозапина с замедленным высвобождением и способ их получения |
RU2613192C1 (ru) * | 2016-02-18 | 2017-03-15 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Таблетки клозапина с пролонгированным высвобождением |
US20200046716A1 (en) * | 2017-02-03 | 2020-02-13 | Jubilant Generics Limited | Lamotrigine suspension dosage form |
EP3672581A4 (fr) | 2017-08-24 | 2021-05-19 | Adamas Pharma, LLC | Compositions d'amantadine, leurs préparation, et procédés d'utilisation |
SG11202003391XA (en) * | 2017-10-27 | 2020-05-28 | Chang Gung Memorial Hospital Linkou | Method for assessing the risk of cutaneous adverse drug reactions induced by anti-epileptic drug lamotrigine, detection reagent thereof and use thereof |
US10213394B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
US20190247331A1 (en) | 2018-02-15 | 2019-08-15 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
US10213393B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság | Composition and method for treating neurological disease |
CN114948868B (zh) * | 2021-04-16 | 2023-04-14 | 上海奥科达医药科技股份有限公司 | 一种拉莫三嗪水合物的晶体形式、其制备方法及包含其的组合物 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704295A (en) * | 1983-09-19 | 1987-11-03 | Colorcon, Inc. | Enteric film-coating compositions |
US4556552A (en) * | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
JPH0667828B2 (ja) * | 1985-10-09 | 1994-08-31 | 日研化学株式会社 | バルプロ酸ナトリウムの持続性顆粒製剤 |
US4775536A (en) * | 1986-02-24 | 1988-10-04 | Bristol-Myers Company | Enteric coated tablet and process for making |
US4816262A (en) * | 1986-08-28 | 1989-03-28 | Universite De Montreal | Controlled release tablet |
GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
DE69207863T2 (de) * | 1991-11-13 | 1996-06-05 | Glaxo Canada | Vorrichtung zur kontrollierten Wirkstoffreigabe |
US5733575A (en) * | 1994-10-07 | 1998-03-31 | Bpsi Holdings, Inc. | Enteric film coating compositions, method of coating therewith, and coated forms |
AUPN605795A0 (en) * | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
AU4078897A (en) * | 1996-08-23 | 1998-03-06 | Algos Pharmaceutical Corporation | Anticonvulsant containing composition for treating neuropathic pain |
GB9625795D0 (en) * | 1996-12-12 | 1997-01-29 | Smithkline Beecham Plc | Novel treatment |
US6046716A (en) * | 1996-12-19 | 2000-04-04 | Colorado Microdisplay, Inc. | Display system having electrode modulation to alter a state of an electro-optic layer |
CA2216215A1 (fr) * | 1997-04-05 | 1998-10-05 | Isa Odidi | Formulations a liberation prolongee, utilisant des polymeres intelligents, avec caracteristiques de mouillabilite opposees, correspondant a une hydrophobie et a une hydrophilie |
GB9726987D0 (en) * | 1997-12-22 | 1998-02-18 | Glaxo Group Ltd | Compounds |
KR20010075676A (ko) * | 1998-11-02 | 2001-08-09 | 스톤 스티븐 에프. | 활성 제제의 제어 수송 |
GB9930079D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
GB0024517D0 (en) * | 2000-10-06 | 2000-11-22 | Glaxo Group Ltd | Use of medicaments |
DE10224170A1 (de) * | 2002-05-31 | 2003-12-11 | Desitin Arzneimittel Gmbh | Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung |
PL213565B1 (pl) * | 2002-07-29 | 2013-03-29 | Glaxo Group Ltd | Preparat o przedluzonym uwalnianiu zawierajacy lamotrygine |
-
2003
- 2003-07-28 PL PL374982A patent/PL213565B1/pl unknown
- 2003-07-28 TW TW092120477A patent/TWI342213B/zh not_active IP Right Cessation
- 2003-07-28 KR KR1020057001633A patent/KR100882707B1/ko active IP Right Grant
- 2003-07-28 RU RU2005105353/14A patent/RU2325163C2/ru active
- 2003-07-28 JP JP2004525362A patent/JP4744142B2/ja not_active Expired - Lifetime
- 2003-07-28 AT AT03766343T patent/ATE424827T1/de active
- 2003-07-28 DE DE60326590T patent/DE60326590D1/de not_active Expired - Lifetime
- 2003-07-28 AU AU2003260336A patent/AU2003260336C1/en not_active Expired
- 2003-07-28 MX MXPA05001243A patent/MXPA05001243A/es active IP Right Grant
- 2003-07-28 PT PT03766343T patent/PT1524981E/pt unknown
- 2003-07-28 ES ES03766343T patent/ES2323268T3/es not_active Expired - Lifetime
- 2003-07-28 DK DK03766343T patent/DK1524981T3/da active
- 2003-07-28 CN CNB038223716A patent/CN100363007C/zh not_active Expired - Lifetime
- 2003-07-28 NZ NZ537885A patent/NZ537885A/en not_active IP Right Cessation
- 2003-07-28 CA CA002493301A patent/CA2493301A1/fr not_active Withdrawn
- 2003-07-28 BR BRPI0313148A patent/BRPI0313148B8/pt active IP Right Grant
- 2003-07-28 EP EP03766343A patent/EP1524981B1/fr not_active Expired - Lifetime
- 2003-07-28 MY MYPI20032831A patent/MY141049A/en unknown
- 2003-07-28 AR AR20030102702A patent/AR040709A1/es not_active Application Discontinuation
- 2003-07-28 SI SI200331585T patent/SI1524981T1/sl unknown
- 2003-07-28 WO PCT/EP2003/008368 patent/WO2004012741A1/fr active IP Right Grant
- 2003-07-29 US US10/629,177 patent/US20050032799A1/en not_active Abandoned
-
2005
- 2005-01-20 IL IL166424A patent/IL166424A/en unknown
- 2005-01-28 MA MA28074A patent/MA27509A1/fr unknown
- 2005-01-28 CO CO05007005A patent/CO5680405A2/es not_active Application Discontinuation
- 2005-02-22 NO NO20050948A patent/NO334221B1/no not_active IP Right Cessation
- 2005-02-23 IS IS7707A patent/IS2681B/is unknown
- 2005-09-22 HK HK05108373.5A patent/HK1077003A1/xx not_active IP Right Cessation
-
2009
- 2009-05-29 CY CY20091100580T patent/CY1109119T1/el unknown
-
2010
- 2010-10-15 JP JP2010232745A patent/JP2011057683A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27509A1 (fr) | Formulations a liberation prolongee contenant de la lamotrigine | |
EP1562897A4 (fr) | Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer | |
TNSN99006A1 (fr) | 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99252A1 (fr) | Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant. | |
SE0001899D0 (sv) | New compounds | |
GB0318447D0 (en) | Therapeutic agents | |
TNSN02014A1 (fr) | Composes nouveaux agonistes de ppar et compositions les contenant | |
MA27427A1 (fr) | Composes de benzimidazole-1-yl-thiophene utilises en cancerotherapie | |
GB0225475D0 (en) | Therapeutic agents | |
TNSN01125A1 (fr) | Compositions pharmaceutiques comprenant un inhibiteur de cetp et de l'atorvastatine | |
DE60124684D1 (de) | Sulfonamido-substituierte verbrückte bicycloalkylderivative | |
ECSP045429A (es) | Combinacion de compuestos organicos | |
MA24729A1 (fr) | Macrolides nouveaux. | |
BR0315296A (pt) | Derivados do ciclohexanol espirocìclicos | |
MA30784B1 (fr) | Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs. | |
TNSN00228A1 (fr) | Derives de benzimidazole nouveaux, et compositions les contenant | |
TNSN02021A1 (fr) | Derives de benzimidazole nouveaux, et compositions les contenant | |
BR0008059A (pt) | Composições de valdecoxib | |
TNSN02008A1 (fr) | Derives d'acides isophtalique nouveaux inhibiteurs de mmp, et compositions les contenant | |
BRPI0408396A (pt) | pelìculas de dissolução rápida, consumìveis por via oral, contendo agentes farmaceuticamente ativos | |
GB0225474D0 (en) | Therapeutic agents | |
ECSP034922A (es) | Pirrolopirimidinas | |
NO20042596L (no) | Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1 | |
MXPA04006280A (es) | Compuestos espiroazaciclicos como moduladores de receptor de monoamina. | |
DE60030741D1 (de) | Chinazoline verbindungen als heilmittel |